| Immune thrombocytopenic purpura
Alvaiz vs Privigen
Side-by-side clinical, coverage, and cost comparison for immune thrombocytopenic purpura.Deep comparison between: Alvaiz vs Privigen with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPrivigen has a higher rate of injection site reactions vs Alvaiz based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Privigen but not Alvaiz, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Alvaiz
Privigen
At A Glance
Oral
Daily
TPO-receptor agonist
IV infusion
Every 3-4 weeks
Intravenous immunoglobulin (IVIG)
Indications
- Immune thrombocytopenic purpura
- Hepatitis C, Chronic
- Severe Aplastic Anemia
- Congenital agammaglobulinemia
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Immune thrombocytopenic purpura
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Dosing
Immune thrombocytopenic purpura Initiate at 36 mg orally once daily (18 mg for East-/Southeast-Asian ancestry or hepatic impairment; 9 mg for both); adjust in 18-mg increments to maintain platelet count >=50 x 10^9/L; maximum 54 mg daily.
Hepatitis C, Chronic Initiate at 18 mg orally once daily; adjust in 18-mg increments every 2 weeks to achieve platelet count needed to initiate or maintain pegylated interferon and ribavirin therapy; maximum 72 mg daily; discontinue when antiviral therapy is discontinued.
Severe Aplastic Anemia Initiate at 36 mg orally once daily (18 mg for East-/Southeast-Asian ancestry or hepatic impairment); adjust in 36-mg increments every 2 weeks to maintain platelet count >=50 x 10^9/L; maximum 108 mg daily.
Congenital agammaglobulinemia, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency 200-800 mg/kg IV every 3-4 weeks.
Immune thrombocytopenic purpura 1 g/kg IV daily for 2 consecutive days (total dose 2 g/kg).
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Loading dose: 2 g/kg IV in divided doses over 2-5 consecutive days; maintenance dose: 1 g/kg IV every 3 weeks.
Contraindications
—
- History of anaphylactic or severe systemic reaction to human immune globulin
- Hyperprolinemia (product contains L-proline stabilizer)
- IgA deficiency with antibodies to IgA and a history of hypersensitivity
Adverse Reactions
Most common (>=3%) Nausea, diarrhea, upper respiratory tract infection, vomiting, urinary tract infection, increased ALT, myalgia, oropharyngeal pain, increased AST, pharyngitis, back pain, influenza, paresthesia, rash
Serious Hemorrhage, thrombotic/thromboembolic complications, hepatic decompensation, hepatotoxicity, cataracts
Postmarketing Skin discoloration including hyperpigmentation and skin yellowing
Most common (>5%) Headache, fatigue, nausea, chills, vomiting, back pain, elevated body temperature, diarrhea, cough, stomach discomfort, asthenia, hypertension, pain in extremity, hemolysis, anemia, leukopenia, rash
Serious Hypersensitivity, aseptic meningitis syndrome, hemolysis, renal dysfunction and acute renal failure, thrombosis, hyperproteinemia, hyponatremia, volume overload, transfusion-related acute lung injury
Postmarketing Decreased neutrophil count, hemoglobinuria, renal failure, photophobia, cerebral edema, pruritus, cardiac arrest, thromboembolism, Stevens-Johnson syndrome, ARDS, seizures, hepatic dysfunction
Pharmacology
Eltrombopag is a TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor (cMpl), initiating signaling cascades that induce proliferation and differentiation of megakaryocytes, leading to increased platelet production.
PRIVIGEN is an intravenous immunoglobulin that supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial and viral agents; the mechanism of action has not been fully elucidated but may include immunomodulatory effects.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Alvaiz
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (1/12)
Privigen
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (0/12)
UnitedHealthcare
Alvaiz
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (0/8)
Privigen
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Alvaiz
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Privigen
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availablePAF Co-Pay Relief: Aplastic Anemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Privigen.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AlvaizView full Alvaiz profile
PrivigenView full Privigen profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.